Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
denileukin diftitox · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| denileukin diftitox | BIOLOGICAL | - |
| dexamethasone | DRUG | - |
DISEASE CHARACTERISTICS: Diagnosis of persistent or recurrent cutaneous T-cell lymphoma (CTCL) and suitable for denileukin diftitox therapy PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Albumin at lea...
Denileukin diftitox is being studied for use in patients with persistent or recurrent T-cell lymphoma, specifically in the context of drug/agent toxicity by tissue or organ. It is an investigational monoclonal antibody being developed by Ligand Pharmaceuticals Incorporated for oncology indications.
Denileukin diftitox is being developed by Ligand Pharmaceuticals Incorporated, which trades under the ticker LGND. The company is conducting clinical research on this investigational monoclonal antibody for oncology applications.
Denileukin diftitox is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
Denileukin diftitox has one completed clinical trial, NCT00006345, titled "Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma." This Phase 2 study was conducted in the United States and enrolled adults aged 18 years and older.
Yes, denileukin diftitox is classified as a monoclonal antibody. It is being investigated as a therapeutic agent in the oncology therapeutic area, specifically for conditions related to drug/agent toxicity by tissue or organ and lymphoma.